Cargando…

Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development

In preparation to create a clinical assay that predicts 1-year survival status of advanced heart failure (AdHF) patients before surgical/interventional therapies and to select the appropriate clinical assay platform for the future assay, we compared the properties of next generation sequencing (NGS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondar, Galyna, Xu, Wenjie, Elashoff, David, Li, Xinmin, Faure-Kumar, Emmanuelle, Bao, Tra-Mi, Grogan, Tristan, Moose, Jim, Deng, Mario C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Biological Methods 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974694/
https://www.ncbi.nlm.nih.gov/pubmed/31976350
http://dx.doi.org/10.14440/jbm.2020.300
_version_ 1783490147358081024
author Bondar, Galyna
Xu, Wenjie
Elashoff, David
Li, Xinmin
Faure-Kumar, Emmanuelle
Bao, Tra-Mi
Grogan, Tristan
Moose, Jim
Deng, Mario C.
author_facet Bondar, Galyna
Xu, Wenjie
Elashoff, David
Li, Xinmin
Faure-Kumar, Emmanuelle
Bao, Tra-Mi
Grogan, Tristan
Moose, Jim
Deng, Mario C.
author_sort Bondar, Galyna
collection PubMed
description In preparation to create a clinical assay that predicts 1-year survival status of advanced heart failure (AdHF) patients before surgical/interventional therapies and to select the appropriate clinical assay platform for the future assay, we compared the properties of next generation sequencing (NGS) used in the gene discovery phase to the NanoString platform used in the clinical assay development phase. In 25 AdHF patients in a tertiary academic medical center from 2015 to 2016, PBMC samples were collected and aliquoted for NGS RNA whole transcriptome sequencing and compared to 770 genes represented on NanoString’s PanCancer IO 360 Gene Expression research panel. Prior to statistical analysis, NanoString and NGS expression values were log transformed. We computed Pearson correlation coefficients for each sample, comparing gene expression values between NanoString and NGS across the set of matched genes and for each of the matched genes across the set of samples. Genes were grouped by average NGS expression, and the NanoString-NGS correlation for each group was computed. Out of 770 genes from the NanoString panel, 734 overlapped between both platforms and showed high intrasample correlation. Within an individual sample, there was an expression-level dependent correlation between both platforms. The low- vs. intermediate/high-expression groups showed NGS average correlation 0.21 vs. 0.58–0.68, respectively, and NanoString average correlation 0.07–0.34 vs. 0.59–0.70, respectively. NanoString demonstrated high reproducibility (R(2) > 0.99 for 100 ng input), sensitivity (probe counts between 100 and 500 detected and quantified), and robustness (similar gene signature scores across different RNA input concentrations, cartridges, and outcomes). Data from NGS and NanoString were highly correlated. These platforms play a meaningful, complementary role in the biomarker development process.
format Online
Article
Text
id pubmed-6974694
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Journal of Biological Methods
record_format MEDLINE/PubMed
spelling pubmed-69746942020-01-23 Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development Bondar, Galyna Xu, Wenjie Elashoff, David Li, Xinmin Faure-Kumar, Emmanuelle Bao, Tra-Mi Grogan, Tristan Moose, Jim Deng, Mario C. J Biol Methods Benchmark In preparation to create a clinical assay that predicts 1-year survival status of advanced heart failure (AdHF) patients before surgical/interventional therapies and to select the appropriate clinical assay platform for the future assay, we compared the properties of next generation sequencing (NGS) used in the gene discovery phase to the NanoString platform used in the clinical assay development phase. In 25 AdHF patients in a tertiary academic medical center from 2015 to 2016, PBMC samples were collected and aliquoted for NGS RNA whole transcriptome sequencing and compared to 770 genes represented on NanoString’s PanCancer IO 360 Gene Expression research panel. Prior to statistical analysis, NanoString and NGS expression values were log transformed. We computed Pearson correlation coefficients for each sample, comparing gene expression values between NanoString and NGS across the set of matched genes and for each of the matched genes across the set of samples. Genes were grouped by average NGS expression, and the NanoString-NGS correlation for each group was computed. Out of 770 genes from the NanoString panel, 734 overlapped between both platforms and showed high intrasample correlation. Within an individual sample, there was an expression-level dependent correlation between both platforms. The low- vs. intermediate/high-expression groups showed NGS average correlation 0.21 vs. 0.58–0.68, respectively, and NanoString average correlation 0.07–0.34 vs. 0.59–0.70, respectively. NanoString demonstrated high reproducibility (R(2) > 0.99 for 100 ng input), sensitivity (probe counts between 100 and 500 detected and quantified), and robustness (similar gene signature scores across different RNA input concentrations, cartridges, and outcomes). Data from NGS and NanoString were highly correlated. These platforms play a meaningful, complementary role in the biomarker development process. Journal of Biological Methods 2020-01-03 /pmc/articles/PMC6974694/ /pubmed/31976350 http://dx.doi.org/10.14440/jbm.2020.300 Text en © 2013-2020 The Journal of Biological Methods, All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License: http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle Benchmark
Bondar, Galyna
Xu, Wenjie
Elashoff, David
Li, Xinmin
Faure-Kumar, Emmanuelle
Bao, Tra-Mi
Grogan, Tristan
Moose, Jim
Deng, Mario C.
Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title_full Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title_fullStr Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title_full_unstemmed Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title_short Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
title_sort comparing ngs and nanostring platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development
topic Benchmark
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974694/
https://www.ncbi.nlm.nih.gov/pubmed/31976350
http://dx.doi.org/10.14440/jbm.2020.300
work_keys_str_mv AT bondargalyna comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT xuwenjie comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT elashoffdavid comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT lixinmin comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT faurekumaremmanuelle comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT baotrami comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT grogantristan comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT moosejim comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment
AT dengmarioc comparingngsandnanostringplatformsinperipheralbloodmononuclearcelltranscriptomeprofilingforadvancedheartfailurebiomarkerdevelopment